Is there a future for auto-allo HSCT in multiple myeloma?

The Lancet Oncology

Volumn 12, Issue 13, 2011, Pages 1176-1177

  Dispenzieri, Angela ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CORTICOSTEROID; LENALIDOMIDE; THALIDOMIDE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 13; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 16; CHROMOSOME TRANSLOCATION 20; CHROMOSOME TRANSLOCATION 4; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE EXPRESSION PROFILING; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MAINTENANCE THERAPY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SURVIVAL TIME;

FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MULTIPLE MYELOMA;

EID: 82555169801     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70258-3     Document Type: Letter

References (7)

1. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006, 24:929-936.
2. Lokhorst H, Einsele H, Vesole D, et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2011, 28:4521-4530.
3. Kumar SK, Lacy MQ, Dispenzieri A, et al. Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer 2011, published online Aug 25. 10.1002/cncr.26422.
4. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol 2011, on behalf of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN), published online Sept 30.
5. Kumar SK, Mikhael JR, Buadi FK, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009, 84:1095-1110.
6. Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): the NCIC CTG MY.10 Trial. ASH Annual Meeting; Orlando, FL, USA; Dec 4-7, 2010.
7. Kyle RA Role of maintenance therapy after autologous stem cell transplant for multiple myeloma: lessons for cancer therapy. Mayo Clin Proc 2011, 86:419-420.